Evidence map›Paper›PMID 32876839›Full record

ArticleEuropean radiology2021

T1 and T2 MR fingerprinting measurements of prostate cancer and prostatitis correlate with deep learning-derived estimates of epithelium, lumen, and stromal composition on corresponding whole mount histopathology.

Rakesh Shiradkar, Ananya Panda, Patrick Leo, Andrew Janowczyk, Xavier Farre, Nafiseh Janaki, Lin Li, Shivani Pahwa, Amr Mahran, Christina Buzzy and 6 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in European radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 40 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Simultaneous liver TMagnetic resonance in medicine · 2025
    Article
  5. Quantitative Prostate MRI, From theAJR. American journal of roentgenology · 2025
    Review
  6. Article
  7. MRI-based virtual pathology of the prostate.Magma (New York, N.Y.) · 2024
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. MR fingerprinting of the prostate.Magma (New York, N.Y.) · 2022
    Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Rakesh ShiradkarDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, 44106, USA. rxs558@case.edu.ORCID http://orcid.org/0000-0003-2852-3869
Ananya PandaDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Patrick LeoDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, 44106, USA.
Andrew JanowczykDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, 44106, USA.
Xavier FarreDepartment of Public Health, Public Health Agency of Catalonia, Lleida, Catalonia, Spain.
Nafiseh JanakiDepartment of Pathology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Lin LiDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, 44106, USA.
Shivani PahwaDepartment of Radiology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Amr MahranDepartment of Urology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Christina BuzzyDepartment of Urology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Pingfu FuDepartment of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Robin ElliottDepartment of Pathology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Gregory MacLennanDepartment of Pathology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Lee PonskyDepartment of Urology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Vikas GulaniDepartment of Radiology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Anant MadabhushiDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, 44106, USA.
University Hospitals of Cleveland · USCase Western Reserve University · USBrigham and Women's Hospital · USUniversity of Michigan · US

Funding

Computerized histologic image predictor of cancer outcomeR01CA202752 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI FELDMAN, MICHAEL D, GANESAN, SHRIDAR · 2016 to 2020
$3.1M
Quantitative Histomorphometric Risk Classifier (QuHbIC) in HPV + Oropharyngeal CarcinomaR01CA220581 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI KOYFMAN, SHLOMO, LEWIS, JAMES · 2018 to 2023
$3.1M
Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung CancersR01CA216579 · NCI · EMORY UNIVERSITY · PI FU, PINGFU, LLOYD, MARK · 2018 to 2023
$3.1M
MR Fingerprinting and Computerized Decision Support for Prostate CancerR01CA208236 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GULANI, VIKAS, PONSKY, LEE EVAN · 2017 to 2022
$3.0M
Pathology Image Informatics Platform for visualization, analysis and managementU24CA199374 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GURCAN, METIN NAFI, MADABHUSHI, ANANT · 2015 to 2019
$2.9M
RadxTools for assessing tumor treatment response on imagingU01CA248226 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI TIWARI, PALLAVI, VISWANATH, SATISH EASWAR · 2020 to 2022
$1.4M
HistoTools: A suite of digital pathology tools for quality control, annotation and dataset identificationU01CA239055 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI JANOWCZYK, ANDREW ROBERT, MADABHUSHI, ANANT · 2019 to 2022
$1.0M
RadIO: A Novel Radiomics Toolkit to Predict and Characterize Response to Immunotherapy in Stage III Non-Small Cell Lung CancerI01BX004121 · VA · VETERANS HEALTH ADMINISTRATION · PI Anant Madabhushi, Charles J Nock · 2019 to 2026
–
BIOMEDICAL ENGINEERING RESEARCH FACILITIESC06RR012463 · NCRR · CASE WESTERN RESERVE UNIVERSITY · PI KUTINA, KENNETH L · 1997 to 1997
–
BLRD VA I01 BX004121BLRD VA IK6 BX006185DOD Prostate Cancer Research Program Idea Development Award (W81XWH-15-1-0558)DOD Prostate Cancer Research Program Idea Development Award W81XWH-18-1-0524NCI NIH HHS 1R01CA208236-01A1NCI NIH HHS 1U24CA199374-01, R01CA202752-01A1, R01CA208236-01A1, R01 CA216579-01A1, R01 CA220581-01A1, 1U01 CA239055-01NCI NIH HHS R01 CA202752NCI NIH HHS R01 CA208236NCI NIH HHS R01 CA216579NCI NIH HHS R01 CA220581NCI NIH HHS U01 CA239055NCI NIH HHS U01 CA248226NCI NIH HHS U24 CA199374NCRR NIH HHS C06 RR012463U.S. Department of Defense Lung Cancer Investigator-Initiated Translational Research Award (W81XWH-18-1-0440)U.S. Department of Veterans Affairs VA Merit Review Award IBX004121A
6 · The paper itself

Abstract

objectivesTo explore the associations between T1 and T2 magnetic resonance fingerprinting (MRF) measurements and corresponding tissue compartment ratios (TCRs) on whole mount histopathology of prostate cancer (PCa) and prostatitis. MATERIALS AND

methodsA retrospective, IRB-approved, HIPAA-compliant cohort consisting of 14 PCa patients who underwent 3 T multiparametric MRI along with T1 and T2 MRF maps prior to radical prostatectomy was used. Correspondences between whole mount specimens and MRI and MRF were manually established. Prostatitis, PCa, and normal peripheral zone (PZ) regions of interest (ROIs) on pathology were segmented for TCRs of epithelium, lumen, and stroma using two U-net deep learning models. Corresponding ROIs were mapped to T2-weighted MRI (T2w), apparent diffusion coefficient (ADC), and T1 and T2 MRF maps. Their correlations with TCRs were computed using Pearson's correlation coefficient (R). Statistically significant differences in means were assessed using one-way ANOVA.

resultsStatistically significant differences (p < 0.01) in means of TCRs and T1 and T2 MRF were observed between PCa, prostatitis, and normal PZ. A negative correlation was observed between T1 and T2 MRF and epithelium (R = - 0.38, - 0.44, p < 0.05) of PCa. T1 MRF was correlated in opposite directions with stroma of PCa and prostatitis (R = 0.35, - 0.44, p < 0.05). T2 MRF was positively correlated with lumen of PCa and prostatitis (R = 0.57, 0.46, p < 0.01). Mean T2 MRF showed significant differences (p < 0.01) between PCa and prostatitis across both transition zone (TZ) and PZ, while mean T1 MRF was significant (p = 0.02) in TZ.

conclusionSignificant associations between MRF (T1 in the TZ and T2 in the PZ) and tissue compartments on corresponding histopathology were observed. KEY POINTS: • Mean T2 MRF measurements and ADC within cancerous regions of interest dropped with increasing ISUP prognostic groups (IPG). • Mean T1 and T2 MRF measurements were significantly different (p < 0.001) across IPGs, prostatitis, and normal peripheral zone (NPZ). • T2 MRF showed stronger correlations in the peripheral zone, while T1 MRF showed stronger correlations in the transition zone with histopathology for prostate cancer.

Indexed as

Deep LearningProstatic NeoplasmsProstatitisDiffusion Magnetic Resonance ImagingEpitheliumHumansMagnetic Resonance ImagingMaleRetrospective StudiesDeep learningMagnetic resonance imagingProstatectomyProstatic neoplasmsProstatitis

Identifiers

PMID32876839
PMCPMC7882016
OpenAlexW3081869188

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.